Compare CELU & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELU | ATNM |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 31.4M |
| IPO Year | 2019 | 2013 |
| Metric | CELU | ATNM |
|---|---|---|
| Price | $0.44 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 182.4K | ★ 233.5K |
| Earning Date | 12-01-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | 0.04 | ★ 0.53 |
| Revenue | ★ $26,550,000.00 | $90,000.00 |
| Revenue This Year | $165.42 | $29,066.67 |
| Revenue Next Year | $305.36 | N/A |
| P/E Ratio | $11.70 | ★ $2.06 |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.46 | $0.74 |
| 52 Week High | $2.55 | $1.72 |
| Indicator | CELU | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 25.58 | 35.22 |
| Support Level | N/A | $0.91 |
| Resistance Level | $0.83 | $1.21 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 6.38 | 7.30 |
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.